Off-Label Promotion Settlement Includes Optional Preclearance Process
Amarin may submit up to two proposed communications annually about unapproved use of Vascepa, and FDA must respond with any concerns within 60 calendar days.
Amarin may submit up to two proposed communications annually about unapproved use of Vascepa, and FDA must respond with any concerns within 60 calendar days.